

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number  
WO 02/061071 A3

- (51) International Patent Classification<sup>7</sup>: C12N 15/10, 15/13, C07K 16/00, C12P 21/00, C12N 15/09
- (21) International Application Number: PCT/US01/50297
- (22) International Filing Date:  
18 December 2001 (18.12.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/256,380 18 December 2000 (18.12.2000) US
- (71) Applicant (for all designated States except US): DYAX CORP. [US/US]; 300 Technology Square, Cambridge, MA 02139 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): LADNER, Robert, Charles [US/US]; 3827 Green Valley Road, Ijamsville, MD 21754 (US).
- (74) Agents: HALEY, James, F., Jr. et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
12 September 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FOCUSED LIBRARIES OF GENETIC PACKAGES

(57) Abstract: Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies.

WO 02/061071 A3

28

2150-XED

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/50297

A. CLASSIFICATION OF SUBJECT MATTER		
IPC 7	C12N15/10	C12N15/13 C07K16/00 C12P21/00 C12N15/09
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC 7 C07K C12P C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
EPO-Internal, WPI Data, PAJ, EMBASE, MEDLINE, BIOSIS		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 08320 A (MORPHOSYS PROTEINOPTIMIERUNG ;KNAPPIK ACHIM (DE); PACK PETER (DE);) 6 March 1997 (1997-03-06)	5,26,43
Y	page 3 -page 9  page 10, paragraph 4 page 32 -page 35; figures 1,10,11; examples 1,5,7  --- -/--	1-4, 6-25, 27-42
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents :		
*A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the International search		Date of mailing of the International search report
20 January 2003		28/01/2003
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  Mossier, B

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/50297

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KNAPPIK A ET AL: "FULLY SYNTHESIS HUMAN COMBINATORIAL ANTIBODY LIBRARIES (HUCAL) BASED ON MODULAR CONSENSUS FRAMEWORKS AND CDRS RANDOMIZED WITH TRINUCLEOTIDES" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 296, no. 1, 2000, pages 57-86, XP000939143 ISSN: 0022-2836 the whole document	1-43
Y	--- AUJAME L ET AL: "High affinity human antibodies by phage display" HUMAN ANTIBODIES, AMSTERDAM, NL, vol. 8, no. 4, 1997, pages 155-168, XP002105424 ISSN: 1093-2607 the whole document	1-43
A	--- BARBAS C F ET AL: "SEMISYNTHETIC COMBINATORIAL ANTIBODY LIBRARIES: A CHEMICAL SOLUTION TO THE DIVERSITY PROBLEM" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 89, 1 May 1992 (1992-05-01), pages 4457-4461, XP002024223 ISSN: 0027-8424 abstract page 4458, column 2, paragraphs 1,2	1-43
A	--- KRUIF DE J ET AL: "SELECTION AND APPLICATION OF HUMAN SINGLE CHAIN FV ANTIBODY FRAGMENTS FROM A SEMI-SYNTHETIC PHAGE ANTIBODY DISPLAY LIBRARY WITH DESIGNED CDR3 REGIONS" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 248, no. 1, 21 April 1995 (1995-04-21), pages 97-105, XP000646544 ISSN: 0022-2836 abstract; tables 1,2	1-43
A	--- POWELL R ET AL: "CONSTRUCTION, ASSEMBLY AND SELECTION OF COMBINATORIAL ANTIBODY LIBRARIES" GENETIC ENGINEERING WITH PCR, XX, XX, vol. 5, 1998, pages 155-172, XP000981992 the whole document	1-43
	--- -/--	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/50297

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HOOGENBOOM H R ET AL: "Antibody phage display technology and its applications" IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 4, no. 1, 1 June 1998 (1998-06-01), pages 1-20, XP004127382 ISSN: 1380-2933 the whole document</p>	1-43

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/50297

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1,2,22,23, and 43(partially)

A synthetic combinatorial heavy chain CDR1 library comprising sequence and length diversity and the subject matter relating to said library.

2. Claims: 3,4,24,25, and 43(partially)

A synthetic combinatorial heavy chain CDR2 library comprising sequence and length diversity and the subject matter relating to said library.

3. Claims: 5,6,7,8,26,27,28,29 and 43(partially)

A synthetic combinatorial heavy chain CDR3 library comprising sequence and length diversity and the subject matter relating to said library.

4. Claims: 9,10,30,31, and 43(partially)

A synthetic combinatorial kappa light chain CDR1 library comprising sequence and length diversity and the subject matter relating to said library.

5. Claims: 11,32, and 43(partially)

A synthetic combinatorial kappa light chain CDR2 library comprising sequence diversity and the subject matter relating to said library.

6. Claims: 12,13,33,34, and 43(partially)

A synthetic combinatorial kappa light chain CDR3 library comprising sequence and length diversity and the subject matter relating to said library.

7. Claims: 14,15,35,36, and 43(partially)

A synthetic combinatorial lambda light chain CDR1 library comprising sequence and length diversity and the subject matter relating to said library.

8. Claims: 16,37, and 43(partially)

A synthetic combinatorial lambda light chain CDR2 library

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

comprising sequence diversity and the subject matter relating to said library.

9. Claims: 17,18,38,39 and 43(partially)

A synthetic combinatorial lambda light chain CDR3 library comprising sequence and length diversity and the subject matter relating to said library.

10. Claims: 19,20,40,41and 43(partially)

Synthetic combinatorial heavy chain CDR libraries comprising sequence and length diversity and the subject matter relating to said libraries.

11. Claims: 21,42, and 43(partially)

Synthetic combinatorial heavy and light chain CDR libraries comprising sequence and length diversity and the subject matter relating to said libraries.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/50297

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9708320	A	06-03-1997	AT 219517 T 15-07-2002
		AU 725609 B2	12-10-2000
		AU 6874596 A	19-03-1997
		CA 2229043 A1	06-03-1997
		DE 69621940 D1	25-07-2002
		DE 69621940 T2	16-01-2003
		DK 859841 T3	09-09-2002
		WO 9708320 A1	06-03-1997
		EP 0859841 A1	26-08-1998
		ES 2176484 T3	01-12-2002
		JP 2001519643 T	23-10-2001
		US 6300064 B1	09-10-2001



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number  
**WO 02/061071 A2**

(51) International Patent Classification<sup>7</sup>: C12N 15/00

(21) International Application Number: PCT/US01/50297

(22) International Filing Date:  
18 December 2001 (18.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/256,380 18 December 2000 (18.12.2000) US

(71) Applicant and

(72) Inventor: LADNER, Robert, Charles [US/US]; 3827  
Green Valley Road, Ijamsville, MD 21754 (US).

(74) Agents: HALEY, James, F., Jr. et al.; Fish & Neave, 1251  
Avenue of the Americas, New York, NY 10020 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

**Published:**

— without international search report and to be republished  
upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: FOCUSED LIBRARIES OF GENETIC PACKAGES

(57) Abstract: Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies.

WO 02/061071 A2

**FOCUSED LIBRARIES OF GENETIC PACKAGES**

This application claims the benefit under 35 USC  
§ 120 of United States provisional application 60/256,380,  
filed December 18, 2001. The provisional application and  
5 the Tables attached to it are specifically incorporated by  
reference herein.

The present invention relates to focused  
libraries of genetic packages that each display, display  
and express, or comprise a member of a diverse family of  
10 peptides, polypeptides or proteins and collectively  
display, display and express, or comprise at least a  
portion of the focused diversity of the family. The  
focused diversity of the libraries of this invention  
comprises both sequence diversity and length diversity. In  
15 a preferred embodiment, the focused diversity of the  
libraries of this invention is biased toward the natural  
diversity of the selected family. In a more preferred  
embodiment, the libraries are biased toward the natural  
diversity of human antibodies and are characterized by  
20 variegation in their heavy chain and light chain  
complementarity determining regions ("CDRs").

The present invention further relates to vectors  
and genetic packages (e.g., cells, spores or viruses) for  
displaying, or displaying and expressing a focused diverse  
25 family of peptides, polypeptides or proteins. In a

- 2 -

preferred embodiment the genetic packages are filamentous phage or phagemids or yeast. Again, the focused diversity of the family comprises diversity in sequence and diversity in length.

5           The present invention further relates to methods of screening the focused libraries of the invention and to the peptides, polypeptides and proteins identified by such screening.

#### BACKGROUND OF THE INVENTION

10           It is now common practice in the art to prepare libraries of genetic packages that individually display, display and express, or comprise a member of a diverse family of peptides, polypeptides or proteins and collectively display, display and express, or comprise at  
15   least a portion of the amino acid diversity of the family. In many common libraries, the peptides, polypeptides or proteins are related to antibodies (e.g., single chain Fv (scFv), Fv, Fab, whole antibodies or minibodies (i.e., dimers that consist of  $V_H$  linked to  $V_L$ )). Often, they  
20   comprise one or more of the CDRs and framework regions of the heavy and light chains of human antibodies.

          Peptide, polypeptide or protein libraries have been produced in several ways in the prior art. See e.g., Knappik et al., J. Mol. Biol., 296, pp. 57-86 (2000), which  
25   is incorporated herein by references. One method is to capture the diversity of native donors, either naive or immunized. Another way is to generate libraries having synthetic diversity. A third method is a combination of the first two. Typically, the diversity produced by these  
30   methods is limited to sequence diversity, i.e., each member of the library differs from the other members of the family by having different amino acids or variegation at a given

- 3 -

position in the peptide, polypeptide or protein chain. Naturally diverse peptides, polypeptides or proteins, however, are not limited to diversity only in their amino acid sequences. For example, human antibodies are not  
5 limited to sequence diversity in their amino acids, they are also diverse in the lengths of their amino acid chains.

For antibodies, diversity in length occurs, for example, during variable region rearrangements. See e.g., Corbett et al., J. Mol. Biol., 270, pp. 587-97 (1997). The  
10 joining of V genes to J genes, for example, results in the inclusion of a recognizable D segment in CDR3 in about half of the heavy chain antibody sequences, thus creating regions encoding varying lengths of amino acids. The following also may occur during joining of antibody gene  
15 segments: (i) the end of the V gene may have zero to several bases deleted or changed; (ii) the end of the D segment may have zero to many bases removed or changed; (iii) a number of random bases may be inserted between V and D or between D and J; and (iv) the 5' end of J may be  
20 edited to remove or to change several bases. These rearrangements result in antibodies that are diverse both in amino acid sequence and in length.

Libraries that contain only amino acid sequence diversity are, thus, disadvantaged in that they do not  
25 reflect the natural diversity of the peptide, polypeptide or protein that the library is intended to mimic. Further, diversity in length may be important to the ultimate functioning of the protein, peptide or polypeptide. For example, with regard to a library comprising antibody  
30 regions, many of the peptides, polypeptides, proteins displayed, displayed and expressed, or comprised by the genetic packages of the library may not fold properly or their binding to an antigen may be disadvantaged, if

- 4 -

diversity both in sequence and length are not represented in the library.

An additional disadvantage of prior art libraries of genetic packages that display, display and express, or  
5 comprise peptides, polypeptides and proteins is that they are not focused on those members that are based on natural occurring diversity and thus on members that are most likely to be functional. Rather, the prior art libraries, typically, attempt to include as much diversity or  
10 variegation at every amino acid residue as possible. This makes library construction time-consuming and less efficient than possible. The large number of members that are produced by trying to capture complete diversity also makes screening more cumbersome than it needs to be. This  
15 is particularly true given that many members of the library will not be functional.

#### SUMMARY OF THE INVENTION

One objective of this invention is focused libraries of vectors or genetic packages that encode  
20 members of a diverse family of peptides, polypeptides or proteins wherein the libraries encode populations that are diverse in both length and sequence. The diverse length comprising components that contain motifs that are likely to fold and function in the context of the parental  
25 peptide, polypeptide or protein.

Another object of this invention is focused libraries of genetic packages that display, display and express, or comprise a member of a diverse family of peptides, polypeptides and proteins and collectively  
30 display, display and express, or comprise at least a portion of the focused diversity of the family. These libraries are diverse not only in their amino acid

- 5 -

sequences, but also in their lengths. And, their diversity is focused so as to more closely mimic or take into account the naturally-occurring diversity of the specific family that the library represents.

5           Another object of this invention is diverse, but focused, populations of DNA sequences encoding peptides, polypeptides or proteins suitable for display or display and expression using genetic packages (such as phage or phagemids) or other regimens that allow selection of  
10 specific binding components of a library.

          A further object of this invention is focused libraries comprising the CDRs of human antibodies that are diverse in both their amino acid sequence and in their length (examples of such libraries include libraries of  
15 single chain Fv (scFv), Fv, Fab, whole antibodies or minibodies (i.e., dimers that consist of  $V_H$  linked to  $V_L$ )). Such regions may be from the heavy or light chains or both and may include one or more of the CDRs of those chains. More preferably, the diversity or variegation occurs in all  
20 of the heavy chain and light chain CDRs.

          It is another object of this invention to provide methods of making and screening the above libraries and the peptides, polypeptides and proteins obtained in such screening.

25           Among the preferred embodiments of this invention are the following:

          1. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related  
30 peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by

- 6 -

variegated DNA sequences that encode a heavy chain CDR1 selected from the group consisting of:

(1)  $\langle 1 \rangle_1 Y_2 \langle 1 \rangle_3 M_4 \langle 1 \rangle_5$ , wherein  $\langle 1 \rangle$  is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y;

(2)  $(S/T)_1 (S/G/X)_2 (S/G/X)_3 Y_4 Y_5 W_6 (S/G/X)_7$ , wherein (S/T) is a 1:1 mixture of S and T residues, (S/G/X) is a mixture of 0.2025 S, 0.2025 G and 0.035 of each of amino acid residues A, D, E, F, H, I, K, L, M, N, P, Q, R, T, V, W, and Y;

(3)  $V_1 S_2 G_3 G_4 S_5 I_6 S_7 \langle 1 \rangle_8 \langle 1 \rangle_9 \langle 1 \rangle_{10} Y_{11} Y_{12} W_{13} \langle 1 \rangle_{14}$ , wherein  $\langle 1 \rangle$  is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; and

(4) mixtures of vectors or genetic packages characterized by any of the above DNA sequences, preferably in the ratio: HC CDR1s (1):(2):(3)::0.80:0.17:0.02.

2. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody facility, the vectors or genetic packages being characterized by variegated DNA sequences that encode a heavy chain CDR2 selected from the group consisting of:

(1)  $\langle 2 \rangle I \langle 2 \rangle \langle 3 \rangle SGG \langle 1 \rangle T \langle 1 \rangle YADSVKG$ , wherein  $\langle 1 \rangle$  is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y;  $\langle 2 \rangle$  is an equimolar mixture of each of amino acid residues Y, R, W, V, G, and S; and  $\langle 3 \rangle$  is an equimolar

- 7 -

mixture of each of amino acid residues P, S, and G or an equimolar mixture of P and S;

(2) <1>I<4><1><1><G><5><1><1><1>YADSVK<sub>G</sub>,  
wherein <1> is an equimolar mixture of each of amino acid  
5 residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V,  
W, and Y; <4> is an equimolar mixture of residues D, I, N,  
S, W, Y; and <5> is an equimolar mixture of residues S, G,  
D and N;

(3) <1>I<4><1><1><G><5><1><1>YNPSLK<sub>G</sub>, wherein  
10 <1> is an equimolar mixture of each of amino acid residues  
A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;  
and <4> and <5> are as defined above;

(4) <1>I<8>S<1><1><1>GGYY<1>YAASVK<sub>G</sub>,  
wherein <1> is an equimolar mixture of each amino acid  
15 residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V,  
W and Y; <8> is 0.27 R and 0.027 of each of  
ADEF<sub>G</sub>HIKLMNPQSTVWY; and

(5) mixtures of vectors or genetic packages  
characterized by any of the above DNA sequences, preferably  
20 in the ratio: HC CDR2s: (1)/(2) (equimolar):  
(3):(4)::0.54:0.43:0.03.

3. A focused library of vectors or genetic  
packages that display, display and express, or comprise a  
member of a diverse family of human antibody related  
25 peptides, polypeptides and proteins and collectively  
display, display and express, or comprise at least a  
portion of the diversity of the antibody family, the  
vectors or genetic packages being characterized by  
variegated DNA sequences that encode a heavy chain CDR3  
30 selected from the group consisting of:

(1) YYCA21111YFDYW<sub>G</sub>, wherein 1 is an  
equimolar mixture of each amino acid residues A, D, E, F,



- 8 -

G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(2) YYCA2111111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(3) YYCA21111111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(4) YYCAR111S2S3111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of Y and W;

(5) YYCA2111CSG11CY1YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(6) YYCA211S1TIFG11111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(7) YYCAR111YY2S3344111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; 2 is an equimolar mixture of D and G; and 3 is an equimolar mixture of S and G;

(8) YYCAR1111YC2231CY111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of T, D and G; and

- 9 -

(9) mixtures of vectors or genetic packages characterized by any of the above DNA sequences, preferably the HC CDR3s (1) through (8) are in the following proportions in the mixture:

- |    |  |  |
|----|--|--|
| 5  | (1)  | 0.10                                   |
|    | (2)  | 0.14                                   |
|    | (3)  | 0.25                                   |
|    | (4)  | 0.13                                   |
|    | (5)  | 0.13                                   |
| 10 | (6)  | 0.11                                   |
|    | (7)  | 0.04 and                               |
|    | (8)  | 0.10; and more preferably the HC CDR3s |
|    | (1) through (8) are in the following proportions in the mixture: |  |
| 15 | (1)  | 0.02                                   |
|    | (2)  | 0.14                                   |
|    | (3)  | 0.25                                   |
|    | (4)  | 0.14                                   |
|    | (5)  | 0.14                                   |
| 20 | (6)  | 0.12                                   |
|    | (7)  | 0.08 and                               |
|    | (8)  | 0.11.                                  |

Preferably, 1 in one or all of HC CDR3s (1) through (8) is 0.095 of each of G and Y and 0.048 of each  
25 of A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, and W.

4. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively  
30 display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by

- 10 -

variegated DNA sequences that encodes a kappa light chain CDR1 selected from the group consisting of:

(1) RASQ<1>V<2><2><3>LA

(2) RASQ<1>V<2><2><2><3>LA;

5 wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <3> is 0.2Y and 0.044 each of ADEFGHIKLMNPQRTVW and Y; and

(3) mixtures of vectors or genetic packages  
10 characterized by any of the above DNA sequences, preferably in the ratio CDR1s (1):(2)::0.68:0.32.

5. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related  
15 peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a kappa light chain  
20 CDR2 having the sequence:

<1>AS<2>R<4><1>,

wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <4> is 0.2 A and )0.044 each of  
25 DEFGHIKLMNPQRTVWY.

6. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related  
peptides, polypeptides and proteins and collectively  
30 display, display and express, or comprise at least a portion of the diversity of the antibody family, the

- 11 -

vectors or genetic packages being characterized by variegated DNA sequences that encode a kappa light chain CDR3 selected from the groups consisting of:

(1) QQ<3><1><1><1>P<1>T,

5 wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <3> is 0.2 Y and 0.044 each of ADEFGHIKLMNPQRTVW;

(2) QQ33111P, wherein 1 and 3 are as defined in (1) above;

10 (3) QQ3211PP1T, wherein 1 and 3 are as defined in (1) above and 2 is 0.2 S and 0.044 each of ADEFGHIKLMNPQRTVWY; and

(4) mixtures of vectors or genetic packages characterized by any of the above DNA sequences, preferably  
15 in the ratio CDR3s (1):(2):(3)::0.65:0.1:0.25.

7. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively  
20 display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a lambda light chain CDR1 selected from the group consisting of:

25 (1) TG<1>SS<2>VG<1><3><2><3>VS,

wherein <1> is 0.27 T, 0.27 G and 0.027 each of ADEFHIKLMNPQRSVWY, <2> is 0.27 D, 0.27 N and 0.027 each of AEFNGHIKLMNPQRSTVWY, and <3> is 0.36 Y and 0.036 each of ADEFGHIKLMNPQRTVW;

30 (2) G<2><4>L<4><4><4><3><4><4>,

- 12 -

wherein <2> is as defined in (1) above and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; and

(3) mixtures of vectors or genetic packages  
5 characterized by any of the above DNA sequences, preferably in the ratio CDR1s (1):(2)::0.67:0.33.

8. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related  
10 peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a lambda light chain  
15 CDR2 has the sequence:

<4><4><4><2>RPS,

wherein <2> is 0.27 D, 0.27 N, and 0.027 each of ADEFGHIKLMNPQRSTVWY and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW.

20 9. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a  
25 portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a lambda light chain CDR3 selected from the group consisting of:

(1) <4><5><4><2><4>S<4><4><4><4>V,

30 wherein <2> is 0.27 D, 0.27 N, and 0.027 each of ADEFGHIKLMNPQRSTVWY; <4> is an equimolar mixture of amino

- 13 -

acid residues ADEFGHIKLMNPQRSTVW; and <5> is 0.36 S and 0.0355 each of ADEFGHIKLMNPQRTVWY;

(2) <5>SY<1><5>S<5><1><4>V, wherein <1> is an equimolar mixture of ADEFGHIKLMNPQRSTVWY; and <4> and  
5 <5> are as defined in (1) above; and

(3) mixtures of vectors or genetic packages characterized by any of the above DNA sequences, preferably in the ratio CDR3s (1):(2)::1:1.

10 10. A focused library comprising variegated DNA sequences that encode a heavy chain CDR selected from the group consisting of:

(1) one or more of the heavy chain CDR1s of paragraph 1 above;

(2) one or more of the heavy chain CDR2s of  
15 paragraph 2 above;

(3) one or more of the heavy chain CDR3s of paragraph 3 above; and

(4) mixtures of vectors or genetic packages characterized by (1), (2) and (3).

20 11. The focused library comprising one or more of the variegated DNA sequences that encodes a heavy chain CDR of paragraphs 1, 2 and 3 and further comprising variegated DNA sequences that encodes a light chain CDR selected from the group consisting of

25 (1) one or more the kappa light chain CDR1s of paragraph 4;

(2) the kappa light chain CDR2 of paragraph 5;

(3) one or more of the kappa light chain  
30 CDR3s of paragraph 6;

- 14 -

(4) one or more of the kappa light chain CDR1s of paragraph 7;

(5) the lambda light chain CDR2 of paragraph 8;

5 (6) one or more of the lambda light chain CDR3s of paragraph 9; and

(7) mixtures of vectors and genetic packages characterized by one or more of (1) through (6).

10 12. A population of variegated DNA sequences as described in paragraphs 1-11 above.

13. A population of vectors comprising the variegated DNA sequences as described in paragraphs 1-11 above.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

15 Antibodies ("Ab") concentrate their diversity into those regions that are involved in determining affinity and specificity of the Ab for particular targets. These regions may be diverse in sequence or in length. Generally, they are diverse in both ways. However, within  
20 families of human antibodies the diversities, both in sequence and in length, are not truly random. Rather, some amino acid residues are preferred at certain positions of the CDRs and some CDR lengths are preferred. These preferred diversities account for the natural diversity of  
25 the antibody family.

According to this invention, and as more fully described below, libraries of vectors and genetic packages that more closely mirror the natural diversity, both in

- 15 -

sequence and in length, of antibody families, or portions thereof are prepared and used.

### **Human Antibody Heavy Chain Sequence and Length Diversity**

#### **(a) Framework**

5           The heavy chain ("HC") Germ-Line Gene (GLG) 3-23 (also known as VP-47) accounts for about 12% of all human Abs and is preferred as the framework in the preferred embodiment of the invention. It should, however, be understood that other well-known frameworks, such as 4-34,  
10 3-30, 3-30.3 and 4-30.1, may also be used without departing from the principles of the focused diversities of this invention.

          In addition, JH4 (YFDYWGQGTLVTUSS) occurs more often than JH3 in native antibodies. Hence, it is  
15 preferred for the focused libraries of this invention. However, JH3 (AFDIWGQGTMTVSS) could as well be used.

#### **(b) Focused Length Diversity: CDR1, 2 and 3**

##### **(i) CDR1**

          For CDR1, GLGs provide CDR1s only of the lengths  
20 5, 6, and 7. Mutations during the maturation of the V-domain gene, however, can lead to CDR1s having lengths as short as 2 and as long as 16. Nevertheless, length 5 predominates. Accordingly, in the preferred embodiment of this invention, the preferred HC CDR1 is 5 amino acids,  
25 with less preferred CDR1s having lengths of 7 and 14. In the most preferred libraries of this invention, all three lengths are used in proportions similar to those found in natural antibodies.



- 16 -

**(ii) CDR2**

GLGs provide CDR2s only of the lengths 15-19, but mutations during maturation may result in CDR2s of lengths from 16 to 28 amino acids. The lengths 16 and 17  
5 predominate in mature Ab genes. Accordingly, length 17 is the preferred length for HC CDR2 of the present invention. Less preferred HC CDR2s of this invention have lengths 16 and 19. In the most preferred focused libraries of this invention, all three lengths are included in proportions  
10 similar to those found in natural antibody families.

**(iii) CDR3**

HC CDR3s vary in length. About half of human HCs consist of the components: V::nz::D::ny::JHn where V is a V gene, nz is a series of bases (mean 12) that are  
15 essentially random, D is a D segment, often with heavy editing at both ends, ny is a series of bases (mean 6) that are essentially random, and JH is one of the six JH segments, often with heavy editing at the 5' end. The D segments appear to provide spacer segments that allow  
20 folding of the IgG. The greatest diversity is at the junctions of V with D and of D with JH.

In the preferred libraries of this invention both types of HC CDR3s are used. In HC CDR3s that have no identifiable D segment, the structure is V::nz::JHn where  
25 JH is usually edited at the 5' end. In HC CDR3s that have an identifiable D segment, the structure is V::nz::D::ny::JHn.

- 17 -

**(c) Focused Sequence Diversity: CDR1, 2 and 3****(i) CDR1**

In 5 amino acid length CDR1, examination of a 3D model of a humanized Ab showed that the side groups of residues 1, 3, and 5 were directed toward the combining pocket. Consequently, in the focused libraries of this invention, each of these positions may be selected from any of the native amino acid residues, except cysteine ("C"). Cysteine can form disulfide bonds, which are an important component of the canonical Ig fold. Having free thiol groups could, thus, interfere with proper folding of the HC and could lead to problems in production or manipulation of selected Abs. Thus, in the focused libraries of this invention cysteine is excluded from positions 1, 3 and 5 of the preferred 5 amino acid CDR1s. The other 19 natural amino acids residues may be used at positions 1, 3 and 5. Preferably, each is present in equimolar ratios in the variegated libraries of this invention.

3D modeling also suggests that the side groups of residue 2 in a 5 amino acid CDR1 are directed away from the combining pocket. Although this position shows substantial diversity, both in GLG and mature genes, in the focused libraries of this invention this residue is preferably Tyr (Y) because it occurs in 681/820 mature antibody genes. However, any of the other native amino acid residues, except Cys (C), could also be used at this position.

For position 4, there is also some diversity in GLG and mature antibody genes. However, almost all mature genes have uncharged hydrophobic amino acid residues: A, G, L, P, F, M, W, I, V, at this position. Inspection of a 3D model also shows that the side group of residue 4 is packed into the innards of the HC. Thus, in the preferred embodiment of this invention which uses framework 3-23,

- 18 -

residue 4 is preferably Met because it is likely to fit very well into the framework of 3-23. With other frameworks, a similar fit consideration is used to assign residue 4.

5                   Thus, the most preferred HC CDR1 of this invention consists of the amino acid sequence  $\langle 1 \rangle Y \langle 1 \rangle M \langle 1 \rangle$  where  $\langle 1 \rangle$  can be any one of amino acid residues: A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y (not C), preferably present at each position in an equimolar amount.  
10 This diversity is shown in the context of a framework 3-23:JH4 in Table 1. It has a diversity of 6859-fold.

                  The two less preferred HC CDR1s of this invention have length 7 and length 14. For length 7, a preferred variegation is  $(S/T)_1(S/G/\langle 1 \rangle)_2(S/G/\langle 1 \rangle)_3Y_4Y_5W_6(S/G/\langle 1 \rangle)_7$ ;  
15 where (S/T) indicates an equimolar mixture of Ser and Thr codons; (S/G/ $\langle 1 \rangle$ ) indicates a mixture of 0.2025 S, 0.2025 G, and 0.035 for each of A, D, E, F, H, I, K, L, M, N, P, Q, R, T, V, W, Y. This design gives a predominance of Ser and Gly at positions 2, 3, and 7, as occurs in mature HC  
20 genes. For length 14, a preferred variegation is VSGGSIS $\langle 1 \rangle \langle 1 \rangle \langle 1 \rangle Y Y W \langle 1 \rangle$ , where  $\langle 1 \rangle$  is an equimolar mixture of the 19 native amino acid residues, except Cys (C).

                  The DNA that encodes these preferred HC CDR1s is preferably synthesized using trinucleotide building blocks  
25 so that each amino acid residue is present in essentially equimolar or other described amounts. The preferred codons for the  $\langle 1 \rangle$  amino acid residues are gct, gat, gag, ttt, ggt, cat, att, aag, ctt, atg, aat, cct, cag, cgt, tct, act, gtt, tgg, and tat. Of course, other codons for the chosen  
30 amino acid residue could also be used.

                  The diversity oligonucleotide (ON) is preferably synthesized from *BspEI* to *BstXI* (as shown in Table 1) and can, therefore, be incorporated either by PCR synthesis

- 19 -

using overlapping ONs or introduced by ligation of  
BspEI/BstXI-cut fragments. Table 2 shows the  
oligonucleotides that embody the specified variegations of  
the preferred length 5 HC CDR1s of this invention. PCR  
5 using ON-R1V1vg, ON-R1top, and ON-R1bot gives a dsDNA  
product of 73 base pairs, cleavage with BspEI and BstXI  
trims 11 and 13 bases from the ends and provides cohesive  
ends that can be ligated to similarly cut vector having the  
3-23 domain shown in Table 1. Replacement of ON-R1V1vg  
10 with either ONR1V2vg or ONR1V3vg (see Table 2) allows  
synthesis of the two alternative diversity patterns -- the  
7 residue length and the 14 residue length HC CDR1.

The more preferred libraries of this invention  
comprise the 3 preferred HC CDR1 length diversities. Most  
15 preferably, the 3 lengths should be incorporated in  
approximately the ratios in which they are observed in  
antibodies selected without reference to the length of the  
CDRs. For example, one sample of 1095 HC genes have the  
three lengths present in the ratio:  
20 L=5:L=7:L=14::820:175:23::0.80:0.17:0.02. This is the  
preferred ratio in accordance with this invention.

(ii) CDR2

Diversity in HC CDR2 was designed with the same  
considerations as for HC CDR1: GLG sequences, mature  
25 sequences and 3D structure. A preferred length for CDR2 is  
17, as shown in Table 1. For this preferred 17 length  
CDR2, the preferred variegation in accordance with the  
invention is: <2>I<2><3>SGG<1>T<1>YADSVKG, where <2>  
indicates any amino acid residue selected from the group of  
30 Y, R, W, V, G and S (equimolar mixture), <3> is P, S and G  
or P and S only (equimolar mixture), and <1> is any native  
amino acid residue except C (equimolar mixture).

- 20 -

ON-R2V1vg shown in Table 3 embodies this diversity pattern. It is preferably synthesized so that fragments of dsDNA containing the *Bst*XI and *Xba*I site can be generated by PCR. PCR with ON-R2V1vg, ON-R2top, and  
 5 ONR2bot gives a dsDNA product of 122 base pairs. Cleavage with *Bst*XI and *Xba*I removes about 10 bases from each end and produces cohesive ends that can be ligated to similarly cut vector that contains the 3-23 gene shown in Table 1.

In an alternative embodiment for a 17 length HC  
 10 CDR2, the following variegation may be used:  
 <1>I<4><1><1>G<5><1><1><1>YADSVKG, where <1> is as described above for the more preferred alternative of HC CDR2; <4> indicates an equimolar mixture of DINSWY, and <5> indicates an equimolar mixture of SGDN. This diversity  
 15 pattern is embodied in ON-R2V2vg shown in Table 3. Preferably, the two embodiments are used in equimolar mixtures in the libraries of this invention.

Other preferred HC CDR2s have lengths 16 and 19.  
 Length 16: <1>I<4><1><1>G<5><1><1>YNPSLKG; Length 19:  
 20 <1>I<8>S<1><1><1>GGYY<1>YAASVKG, wherein <1> is an equimolar mixture of all native amino acid residues except C; <4> is a equimolar mixture of DINSWY; <5> is an equimolar mixture of SGDN; and <8> is 0.27 R and 0.027 of each of residues ADEFGHIKLMNPQSTVWY. Table 3 shows ON-  
 25 R2V3vg which embodies a preferred CDR2 variegation of length 16 and ON-R2V4vg which embodies a preferred CDR2 variegation of length 19. To prepare these variegations ON-R2V3vg may be PCR amplified with ON-R2top and ON-R2bo3 and ON-R2V4vg may be PCR amplified with ON-R2top and ON-R2-  
 30 bo4. See Table 3. In the most preferred embodiment of this invention, all three HC CDR2 lengths are used. Preferably, they are present in a ratio  
 17:16:19::579:464:31::0.54:0.43:0.03.

- 21 -

(iii) CDR3

The preferred libraries of this invention comprise several HC CDR3 components. Some of these will have only sequence diversity. Others will have sequence diversity with embedded D segments to extend the length, while also incorporating sequences known to allow Igs to fold. The HC CDR3 components of the preferred libraries of this invention and their diversities are depicted in Table 4: Components 1-8.

10 This set of components was chosen after studying the sequences of 1383 human HC sequences. The proposed components are meant to fulfill the following goals:

- 1) approximately the same distribution of lengths as seen in native Ab genes;
- 15 2) high level of sequence diversity at places having high diversity in native Ab genes; and
- 3) incorporation of constant sequences often seen in native Ab genes.

Component 1 represents all the genes having lengths 0 to 8 (counting from the YYCAR motif at the end of FR3 to the WG dipeptide motif near the start of the J region, i.e., FR4). Component 2 corresponds to all the genes having lengths 9 or 10. Component 3 corresponds to the genes having lengths 11 or 12 plus half the genes having length 13. Component 4 corresponds to those having length 14 plus half those having length 13. Component 5 corresponds to the genes having length 15 and half of those having length 16. Component 6 corresponds to genes of length 17 plus half of those with length 16. Component 7  
30 corresponds to those with length 18. Component 8 corresponds to those having length 19 and greater. See Table 4.

- 22 -

For each HC CDR3 residue having the diversity <1>, equimolar ratios are preferably not used. Rather, the following ratios are used 0.095 [G and Y] and 0.048 [A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, and W]. Thus, there is a double dose of G and Y with the other residues being in equimolar ratios. For the other diversities, e.g., KR or SG, the residues are present in equimolar mixtures.

In the preferred libraries of this invention the eight components are present in the following fractions: 1 (0.10), 2 (0.14), 3 (0.25), 4 (0.13), 5 (0.13), 6 (0.11), 7 (0.04) and 8 (0.10). See Table 4.

In the more preferred embodiment of this invention, the amounts of the eight components is adjusted because the first component is not complex enough to justify including it as 10% of the library. For example, if the final library were to have  $1 \times 10^9$  members, then  $1 \times 10^8$  sequences would come from component 1, but it has only  $2.6 \times 10^5$  CDR3 sequences so that each one would occur in ~385 CDR1/2 contexts. Therefore, the more preferred amounts of the eight components are 1(0.02), 2(0.14), 3(0.25), 4(0.14), 5(0.14), 6(0.12), 7(0.08), 8(0.11). In accordance with the more preferred embodiment component 1 occurs in ~77 CDR1/2 contexts and the other, longer CDR3s occur more often.

Table 5 shows vgDNA that embodies each of the eight HC CDR3 components shown in Table 4. In Table 5, the oligonucleotides (ON) Ctop25, CtpmA, CBpmB, and CBot25 allow PCR amplification of each of the variegated ONs (vgDNA): C1t08, C2t10, C3t12, C4t14, C5t15, C6t17, C7t18, and C8t19. After amplification, the dsDNA can be cleaved with *Afl*III and *Bst*EII (or *Kpn*I) and ligated to similarly cleaved vector that contains the remainder of the 3-23

- 23 -

domain. Preferably, this vector already contains diversity in one, or both, of CDR1 and CDR2 as disclosed herein. Most preferably, it contains diversity in both the CDR1 and CDR2 regions. It is, of course, to be understood that the various diversities can be incorporated into the vector in any order.

Preferably, the recipient vector originally contains a stuffer in place of CDR1, CDR2 and CDR3 so that there will be no parental sequence that would then occur in the resulting library. Table 6 shows a version of the V3-23 gene segment with each CDR replaced by a short segment that contains both stop codons and restriction sites that will allow specific cleavage of any vector that does not have the stuffer removed. The stuffer can either be short and contain a restriction enzyme site that will not occur in the finished library, allowing removal of vectors that are not cleaved by both *AflIII* and *BstEII* (or *KpnI*) and religated. Alternatively, the stuffer could be 200-400 bases long so that uncleaved or once cleaved vector can be readily separated from doubly cleaved vector.

#### **Human Antibody Light Chain: Sequence and Length Diversity**

##### **(i) Kappa Chain**

##### **(a) Framework**

In the preferred embodiment of this invention, the kappa light chain is built in an A27 framework with a JK1 region. These are the most common V and J regions in the native genes. Other frameworks, such as O12, L2, and A11, and other J regions, such as JK4, however, may be used without departing from the scope of this invention.

##### **(b) CDR1**

In native human kappa chains, CDR1s with lengths of 11, 12, 13, 16, and 17 were observed with length 11



- 24 -

being predominant and length 12 being well represented. Thus, in the preferred embodiments of this invention LC CDR1s of length 11 and 12 are used in an and mixture similar to that observed in native antibodies), length 11 being most preferred. Length 11 has the following sequence: RASQ<1>V<2><2><3>LA and Length 12 has the following sequence: RASQ<1>V<2><2><2><3>LA, wherein <1> is an equimolar mixture of all of the native amino acid residues, except C, <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY, and <3> is 0.2 Y and 0.044 each of A, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W and Y. In the most preferred embodiment of this invention, both CDR1 lengths are used. Preferably, they are present in a ratio of 11:12::154:73::0.68:0.32.

15 (c) CDR2

In native kappa, CDR2 exhibits only length 7. This length is used in the preferred embodiments of this invention. It has the sequence <1>AS<2>R<4><1>, wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRTVWY; <2> is 0.2 S and 0.004 of each of ADEFGHIKLMNPQRTVWY; and <4> is 0.2 A and 0.044 of each of DEFGHIKLMNPQRSTUWY.

(d) CDR3

In native kappa, CDR3 exhibits lengths of 1, 4, 6, 7, 8, 9, 10, 11, 12, 13, and 19. While any of these lengths and mixtures of them can be employed in this invention, we prefer lengths 8, 9 and 10, length 9 being more preferred. For the preferred Length 9, the sequence is QQ<3><1><1><1>P<1>T, wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRTVWY and <3> is 0.2 Y and 0.044 each of ADEFGHIKLMNPQRSVW. Length 8 is preferably QQ33111P and Length 10 is preferably QQ3211PP1T, wherein 1 and 3 are as defined for Length 9 and 2 is S

- 25 -

(0.2) and 0.044 each of ADEFGHIKLMNPQRTVWY. A mixture of all 3 lengths being most preferred (ratios as in native antibodies), i.e., 8:9:10::28:166:63::0.1:0.65:0.25.

Table 7 shows a kappa chain gene of this invention, including a PlacZ promoter, a ribosome-binding site, and signal sequence (M13 III signal). The DNA sequence encodes the GLG amino acid sequence, but does not comprise the GLG DNA sequence. Restriction sites are designed to fall within each framework region so that diversity can be cloned into the CDRs. XmaI and EspI are in FR1, SexAI is in FR2, RsrII is in FR3, and KpnI (or Acc65I) are in FR4. Additional sites are provided in the constant kappa chain to facilitate construction of the gene.

Table 7 also shows a suitable scheme of variegation for kappa. In CDR1, the most preferred length 11 is depicted. However, most preferably both lengths 11 and 12 are used. Length 12 in CDR1 can be construed by introducing codon 51 as <2> (i.e. a Ser-biased mixture). CDR2 of kappa is always 7 codons. Table 7 shows a preferred variegation scheme for CDR2. Table 7 shows a variegation scheme for the most preferred CDR3 (length 9). Similar variegations can be used for CDRs of length 8 and 10. In the preferred embodiment of this invention, those three lengths (8, 9 and 10) are included in the libraries of this invention in the native ratios, as described above.

Table 9 shows series of diversity oligonucleotides and primers that may be used to construct the kappa chain diversities depicted in Table 7.

### 30 (ii) Lambda Chain

#### (a) Framework

The lambda chain is preferably built in a 2a2 framework with an L2J region. These are the most common V

- 26 -

and J regions in the native genes. Other frameworks, such as 3l, 4b, 1a and 6a, and other J regions, such as L1J, L3J and L7J, however, may be used without departing from the scope of this invention.

#### 5 (b) CDR1

In native human lambda chains, CDR1s with length 14 predominate, lengths 11, 12 and 13 also occur. While any of these can be used in this invention, lengths 11 and 14 are preferred. For length 11 the sequence is:  
 10 TG<2><4>L<4><4><4><3><4><4> and for Length 14 the sequence is: TG<1>SS<2>VG<1><3><2><3>VS, wherein <1> is 0.27 T, 0.27 G and 0.027 each of ADEFHIKLMNPQRSVWY; <2> is 0.27 D, 0.27 N and 0.027 each of AEFHGHIKLMNPQRSTVWY; <3> is 0.36 Y and 0.0355 each of ADEFHGHIKLMNPQRSTVW; and <4> is an equimolar  
 15 mixture of amino acid residues ADEFHGHIKLMNPQRSTVWY. Most preferably, mixtures (similar to those occurring in native antibodies) preferably, the ratio is 11:14::23:46::0.33:0.67 of the three lengths are used.

#### (c) CDR2

20 In native human lambda chains, CDR2s with length 7 are by far the most common. This length is preferred in this invention. The sequence of this Length 7 CDR2 is <4><4><4><2>RPS, wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEFHGHIKLMNPQRSTVWY and <4> is an equimolar mixture  
 25 of amino acid residues ADEFHGHIKLMNPQRSTVW.

#### (d) CDR3

In native human lambda chains, CDR3s of length 10 and 11 predominate, while length 9 is also common. Any of these three lengths can be used in the invention. Length  
 30 11 is preferred and mixtures of 10 and 11 more preferred. The sequence of Length 11 is <4><5><4><2><4>S<4><4><4><4>V, where <2> and <4> are as defined for the lambda CDR1 and <5> is 0.36 S and 0.0355 each of ADFFGHIKLMNPQRTVWY. The

- 27 -

sequence of Length 10 is <5>SY<1><5>S<5><1><4>V, wherein  
<1> is an equimolar mixture of ADEFGHIKLMNPQRSTVWY; and <4>  
and <5> are as defined for Length 11. The preferred  
mixtures of this invention comprise an equimolar mixture of  
5 Length 10 and Length 11. Table 8 shows a preferred focused  
lambda light chain diversity in accordance with this  
invention.

Table 9 shows a series of diversity  
oligonucleotides and primers that may be used to construct  
10 the lambda chain diversities depicted in Table 7.

#### **Method of Construction of the Genetic Package**

The diversities of heavy chain and the kappa and  
lambda light chains are best constructed in separate  
vectors. First a synthetic gene is designed to embody each  
15 of the synthetic variable domains. The light chains are  
bounded by restriction sites for *Apa*LI (positioned at the  
very end of the signal sequence) and *Asc*I (positioned after  
the stop codon). The heavy chain is bounded by *Sfi*II  
(positioned within the *Pel*B signal sequence) and *Not*I  
20 (positioned in the linker between CH1 and the anchor  
protein). Signal sequences other than *Pel*B may also need,  
e.g., a M13 pIII signal sequence.

The initial genes are made with "stuffer"  
sequences in place of the desired CDRs. A "Stuffer" is a  
25 sequence that is to be cut away and replaced by diverse DNA  
but which does not allow expression of a functional  
antibody gene. For example, the stuffer may contain  
several stop codons and restriction sites that will not  
occur in the correct finished library vector. For example,  
30 in Table 10, the stuffer for CDR1 of kappa A27 contains a  
*Stu*I site. The vgDNA for CDR1 is introduced as a cassette  
from *Esp*I, *Xma*I, or *Afl*III to either *Sex*AI or *Kas*I. After

- 28 -

the ligation, the DNA is cleaved with *StuI*; there should be no *StuI* sites in the desired vectors.

The sequences of the heavy chain gene with stuffers is depicted in Table 6. The sequences of the  
5 kappa light chain gene with stuffers is depicted in Table 10. The sequence of the lambda light chain gene with stuffers is depicted in Table 11.

In another embodiment of the present intention the diversities of heavy chain and the kappa or lambda  
10 light chains are constructed in a single vector or genetic packages (e.g., for display or display and expression) having appropriate restriction sites that allow cloning of these chains. The processes to construct such vectors are well known and widely used in the art. Preferably, a heavy  
15 chain and Kappa light chain library and a heavy chain and lambda light chain library would be prepared separately. The two libraries, most preferably, will then be mixed in equimolar amounts to attain maximum diversity.

Most preferably, the display is had on the  
20 surface of a derivative of M13 phage. The most preferred vector contains all the genes of M13, an antibiotic resistance gene, and the display cassette. The preferred vector is provided with restriction sites that allow introduction and excision of members of the diverse family  
25 of genes, as cassettes. The preferred vector is stable against rearrangement under the growth conditions used to amplify phage.

In another embodiment of this invention, the diversity captured by the methods of the present invention  
30 may be displayed and/or expressed in a phagemid vector (e.g., pCES1) that displays and/or expresses the peptide, polypeptide or protein. Such vectors may also be used to

- 29 -

store the diversity for subsequent display and/or expression using other vectors or phage.

In another embodiment of this invention, the diversity captured by the methods of the present invention  
5 may be displayed and/or expressed in a yeast vector.

Table 1: 3-23:JH4 CDR1/2 diversity =  $1.78 \times 10^8$

FR1 (VP47/V3-23)-----  
 23 24 25 26 27 28 29 30  
 E V Q L L E S G  
 gaa|ggt|caa|ttg|tta|gag|tct|ggt|  
 MfeI

-----FR1-----  
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45  
 G G L V Q P G G S L R L S C A  
 |ggc|ggt|ctt|ggt|cag|cct|ggt|ggt|tct|tta|cgt|ctt|tct|tgc|gct|

6859-fold diversity

Sites of variegation <1> <1> <1> <1>  
 -----FR1----->|.....CDR1.....|-----FR2-----  
 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60  
 A S G F T F S - Y - M - W V R  
 |gct|tcc|gga|ttc|act|ttc|tct| - |tac| - |atg| - |tgg|ggt|cgc|  
 BspEI BsiWI BstXI.

Sites of variegation-><2> <2> <3>  
 -----FR2----->|...CDR2.....  
 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75  
 Q A P G K G L E W V S - I - -  
 |caa|gct|cct|ggt|aaa|ggt|ttg|gag|tgg|ggt|tct| - |atc| - | - |  
 ....BstXI

<1> <1> 25992-fold diversity in CDR2  
 .....CDR2.....|-----FR3-----  
 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90  
 S G G - T - Y A D S V K G R F  
 |tct|ggg|ggc| - |act| - |tat|gct|gac|tcc|ggt|aaa|ggg|cgc|ttc|

-----FR3-----  
 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105  
 T I S R D N S K N T L Y L Q M  
 |act|atc|tct|aga|gac|aac|tct|tct|aag|aat|act|ctc|tac|ttg|cag|atg|  
 XbaI

-----FR3----->|  
 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120  
 N S L R A E D T A V Y Y C A K  
 |aac|agc|tta|agg|gct|gag|gac|acc|gct|gtc|tac|tac|tgc|gcc|aaa|  
 AflII

.....CDR3.....| Replaced by the various components!  
 121 122 123 124 125 126 127  
 D Y E G T G Y  
 |gac|tat|gaa|ggg|act|ggg|tat|

|-----FR4 --- (JH4)-----  
 Y F D Y W G Q G T L V T V S S  
 |tat|ttc|gat|tat|tgg|ggg|caa|ggg|acc|ctg|gtc|acc|gtc|tct|agt|...  
 KpnI BstEII



<1> = Codons for ADEFGHIKLMNPQRSTVWY (equimolar mixture)  
<2> = Codons for YRWVGS (equimolar mixture)  
<3> = Codons for PS or PS and G (equimolar mixture)

**Table 2: Oligonucleotides used to variegate CDR1 of human HC**

**CDR1 - 5 residues**

(ON-R1V1vg): 5'-ct|tcc|gga|ttc|act|ttc|tct|<1>|tac|<1>|atg|<1>|tgg|gtt|cgc|caa|gct|cct|gg-3'

<1> = Codons of ADEFGHIKLMNPQRSTVWY 1:1

5 (ON-R1top): 5'-cctactgtct|tcc|gga|ttc|act|ttc|tct-3'

(ON-R1bot) [RC]: 5' -tgg|gtt|cgc|caa|gct|cct|ggttgctcactc-3'

**CDR1 - 7 residues**

(ON-R1V2vg) : 5'-ct|tcc|gga|ttc|act|ttc|tct|<6>|<7>|tac|tac|tgg|gtt|cgc|caa|gct|  
cct|gg-3'

10 <6> = Codons for ST, 1:1

$$\langle 7 \rangle = 0.2025(\text{Codons for SG}) + 0.035(\text{Codons for ADEFGHIKLMNPQRTVWY})$$

**CDR1 - 14 residues**

(ON-R1V3vg): 5'-ct|tcc|gga|ttc|act|tct|tct|atc|agc|ggt|ggt|tct|atc|tcc|<1>|<1>|  
tac|tac|tga|<1>|tga|gtt|cgc|caa|gct|cct|gg-3'

15 <1> = Codons for ADEFGHIKLMNPQRSTVWY 1:1

Table 3: Oligonucleotides used to variegate CDR2 of human HC

## CDR2 - 17 residues

(ON-R2V1vg): 5'-ggg|ttg|gag|tgg|ggt|tct|<2>|atc|<2>|<3>|tct|ggt|ggc|<1>|act|<1>|tat|gct|gac|tcc|ggt|aaa|gg-3'

5 (ON-R2top): 5'-ct|tgg|ggt|cgc|caa|gct|cct|ggt|aaa|ggt|ttg|gag|tgg|ggt|tct-3'

(ON-R2bot) [RC]: 5'-tat|gct|gac|tcc|ggt|aaa|ggt|cgc|ttc|act|atc|tct|aga|ttcctgtcac-3'

<1> = Codons for A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y (equimolar mixture)

<2> = Codons for Y, R, W, V, G and S (equimolar mixture)

<3> = Codons for P and S (equimolar mixture) or P, S and G (equimolar mixture)

10 (ON-R2V2vg): 5'-ggg|ttg|gag|tgg|ggt|tct|<1>|atc|<4>|<1>|<1>|ggt|<5>|<1>|<1>|tat|gct|gac|tcc|ggt|aaa|gg-3'

<4> = Codons for DINSWY (equimolar mixture)

<5> = Codons for SGDN, (equimolar mixture)

**CDR2 - 16 residues**

(ON-R2V3vg): 5'-ggg|ttg|gag|tgg|gtt|tct|<1>|atc|<4>|<1>|<1>|<1>|ggg|  
<5>|<1>|<1>|tatt|aac|cct|tcc|ctt|aag|gg-3'

(ON-R2bo3) [RC]: 5'-tat|aac|cct|tcc|ctt|aag|ggg|cgc|ttc|act|atc|tct|aga|ttcctgtcac-3'

**5 CDR2 - 19 residues**

(ON-R2V4vg): 5'-ggg|ttg|gag|tgg|gtt|tct|<1>|atc|<8>|agt|<1>|<1>|  
<1>|ggg|ggg|act|act|<1>|tat|gcc|gct|tcc|gtt|aag|gg-3'

(ON-R2bo4) [RC]: 5'-tat|gcc|gct|tcc|gtt|aag|ggg|cgc|ttc|act|atc|tct|aga|ttcctgtcac-3'

<1>, <2>, <3>, <4> and <5> are as defined above

10 <8> is 0.27 R and 0.027 each of ADEFGHIKLMNPQSTVWY

- 36 -

Table 4: Preferred Components of HC CDR3

<u>Component</u>	<u>Length</u>	<u>Complexity</u>	<u>Fraction of Library</u>	<u>Preferred Adjusted Fraction</u>
5				
1	YYCA21111YFDYWG. (1=any amino acid residue, except C; 2 = K and R)	8 2.6 x 10 <sup>5</sup>	.10	.02
2	YYCA211111YFDYWG. (1=any amino acid residue, except C; 2 = K and R)	10 9.4 x 10 <sup>7</sup>	.14	.14
3	YYCA2111111YFDYWG. (1=any amino acid residue, except C; 2 = K and R)	12 3.4 x 10 <sup>10</sup>	.25	.25
10				
4	YYCAR111S2S3111YFDYWG. (1=any amino acid residue, except C; 2 = S and G; 3 = Y and W)	14 1.9 x 10 <sup>8</sup>	.13	.14
5	YYCA21111CSG11CY1YFDYWG. (1=any amino acid residue, except C; 2 = K and R)	15 9.4 x 10 <sup>7</sup>	.13	.14
15				
6	YYCA211S1TIFG1111YFDYWG. (1=any amino acid residue, except C; 2 = K and R)	17 1.7 x 10 <sup>10</sup>	.11	.12
7	YYCAR111Y2S33Y111YFDYWG. (1=any amino acid residue, except C; 2 = D or G; 3 = S and G)	18 3.8 x 10 <sup>8</sup>	.04	.08
20	YYCAR1111YC2231CY111YFDYWG. (1=any amino acid residue, except C; 2 = S and G; 3 = T, D and G)	19 2.0 x 10 <sup>11</sup>	.10	.11

36

**Table 5: Oligonucleotides used to variegate the eight components of HC CDR3**

(Ctop25): 5'-gctctggtcaac|tta|agg|gct|gag|g-3'

(CtprmA): 5'-gctctggtcaac|tta|agg|gct|gag|gac|acc|gct|gtc|tac|tac|tgc|gcc-3'  
AflII...

## AFLII...

(CBprmB) [RC]: 5'-|tac|ttc|gat|tac|tgg|ggc|caa|ggt|acc|ctg|gtc|acc|tggtccacc-3'

BstEI...

(CBot25) [RC]: 5'-|gggt|acc|ctg|gtc|acc|tcgctccacc-3'

The 20 bases at 3' end of CtrpRNA are identical to the most 5' 20 bases of each of the vgDNA molecules.

Ctop25 is identical to the most 5' 25 bases of CtrpA.

The 23 most 3' bases of CBprmb are the reverse complement of the most 3' 23 bases of each of the vgDNA molecules.

CBot25 is identical to the 25 bases at the 5' end of CBprmB.

**15 Component 1**

(C1t08) ::

5' -cc|gct|gtc|tac|tac|tgc|gcc|<2>|<1>|<1>|<1>|<1>|tac|tgc|ggc|caa|gg-3'

$\langle 1 \rangle = 0.095 \text{ Y} + 0.095 \text{ G} + 0.048$  each of the residues ADEFGHIKLMNPQRSTVW, no C;  $\langle 2 \rangle = \text{K}$  and R (equimolar mixture)

**Component 2**

(C2t10):

5'-cc|gct|gtc|tac|tac|tgc|gcc|&lt;2&gt;|&lt;1&gt;|&lt;1&gt;|&lt;1&gt;|&lt;1&gt;|&lt;1&gt;|&lt;1&gt;|&lt;1&gt;|tac|ttc|gat|tac|tgg|ggc|caa|gg-3'

<1> = 0.095 Y + 0.095 G + 0.048 each of ADEFHIKLMNPQRSTVW, no C; <2> = K and R (equimolar mixture)

**Component 3**

(C3t12):

5'-cc|gct|gtc|tac|tac|tgc|gcc|&lt;2&gt;|&lt;1&gt;|&lt;1&gt;|&lt;1&gt;|&lt;1&gt;|&lt;1&gt;|&lt;1&gt;|&lt;1&gt;|tac|ttc|gat|tac|tgg|ggc|caa|gg-3'

10 <1> = 0.095 Y + 0.095 G + 0.048 each of ADEFHIKLMNPQRSTVW, no C; <2> = K and R (equimolar mixture)

**Component 4**

(C4t140):

5' -cc|gct|gtc|tac|tac|tgc|gcc|cgt|<1>|<1>|<1>|tct|<2>|tct|<3>|<1>|<1>|<1>|tac|ttc|gat|-  
 tac|tgg|ggc|caa|gg-3'

5 <1> = 0.095 Y + 0.095 G + 0.048 each of ADEFHIKLMNPQRSTVW, no C; <2> = S and G (equimolar mixture); <3> = Y and W (equimolar mixture)

**Component 5**

(C5t15):

5' -cc|gct|gtc|tac|tac|tgc|gcc|<2>|<1>|<1>|tgc|tct|ggt|<1>|<1>|tgc|tat|<1>|tac|-  
 10 ttc|gat|tac|tgg|ggc|caa|gg-3'

<1> = 0.095 Y + 0.095 G + 0.048 each of ADEFHIKLMNPQRSTVW, no C; <2> = K and R (equimolar mixture)



## Component 6

(C6t17):

5' -cc|gct|gtc|tac|tac|tgc|gcc|<2>|<1>|tct|<1>|act|atc|ttc|<1>|<1>|<1>|-  
<1>|tac|ttc|gat|tac|tgg|ggc|caa|gg-3'

5  $\langle 1 \rangle = 0.095 \text{ Y} + 0.095 \text{ G} + 0.048 \text{ each of ADEFHIKLMNPQRSTVW}$ , no C;  $\langle 2 \rangle = \text{K and R (equimolar mixture)}$

**Component 8**  
(c8t19):

5' -cc|gct|gtc|tac|tac|tgc|gcc|cgt|<1>|<1>|<1>|<1>|tat|tgc|<2>|<2>|<3>|<1>|tgc|tat| -  
<1>|<1>|<1>|tac|ttc|gat|tac|tgc|caa|gg-3'

5 <1> = 0.095 Y + 0.095 G + 0.048 each of ADEEHKLMNPQRSTVW, no C; <2> = S and G (equimolar mixture); <3> = TDG (equimolar mixture);

Table 6: 3-23::JH4 Stuffers in place of CDRs

```

FR1 (DP47/V3-23)-----
20 21 22      23 24 25 26 27 28 29 30
A  M  A      E  V  Q  L  L  E  S  G
ctgtctgaac  cc atg gcc  gaa|ggt|caa|ttg|tta|gag|tct|ggt|
Scab.....  NcoI.....      MfeI

```

```

-----FR1-----
10 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
    G  G  L  V  Q  P  G  G  S  L  R  L  S  C  A
    |ggc|ggg|ctt|ggt|cag|cct|ggg|ggt|tct|tta|cgt|ctt|tct|tgc|gct|

```

```

-----FR1----->|...CDR1 stuffer....|----FR2-----
15 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
    A  S  G  F  T  F  S  S  Y  A  |  |  W  V  R
    |gct|tcc|gga|ttc|act|ttc|tct|tcg|tac|gct|tag|taa|tgg|ggt|cgc|
    BspEI      BsiWI      BstXI.

```

```

-----FR2----->|...CDR2 stuffer.
61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
Q A P G K G L E W V S I p r I
|caa|gct|cct|ggt|aaa|ggt|ttg|gag|tgg|gtt|tct|taa|cct|agg|tag|
...BstXI                               AvrII..
.....CDR2 stuffer.....|---FR3---
91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
T I S R D N S K N T L Y L Q M
|act|atc|tct|aga|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|
XbaI

-----FR3-----> CDR3 Stuffer----->|
106 107 108 109 110
N S L R A
|aac|agc|tta|agg|gct|tag|taa|agg|cct|taa
AflII                               StuI...
15

```

```
|----- FR4 ----(JH4)-----|
Y F D Y W G G Q G T L V T V S S
|tat|ttc|gat|tat|tgg|ggt|caa|ggt|acc|ctg|gtc|acc|gtc|tct|agt|...
                                     KpnI   BstEII
```

Table 7: A27:JH1 Human Kappa light chain gene

gaggacc attgggcccc ctccgagact ctcgagcgca

Scab..... EcoO109I

XhoI..

ApaI.

5

acgcaattaa tgtgagtttag ctcactcatt aggcacccca ggctttacac tttatgcttc

...-35..

Plac

..-10.

45

cggctcgtat gttgtgtgga attgtgagcg gataacaatt tcacacagga

aacagctatg accatgatta

cgccaagctt tggagccttt tttttggaga ttttcaac

10

PflMI.....

Hind III

M13 III signal sequence (AA seq)----->  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15  
M K K L L F A I P L V V P F Y  
gtg aag aag ctc cta ttt gct atc ccg ctt gtc gtt ccg ttt tac

5 --Signal-->FR1----->  
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30  
S H S A Q S S V L T Q S P G T L  
|agc|cat|agt|gca|caa|tcc|gtc|ctt|act|caa|tct|cct|ggc|act|ctt|  
ApaLI...

10 ----- FR1 ----->| CDR1----->  
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45  
S L S P G E R A T L S C R A S  
|tcg|cta|agc|ccg|ggg|gaa|cgt|gct|acc|tta|agt|tgc|cgt|gct|tcc|  
EspI..... AflII...  
XmaI.....

For CDR1:

<1> ADEFGHIKLMNPQRSTVWY 1:1

$\langle 2 \rangle$  S(0.2) ADEFGHIKLMNPQRTVWY (0.044 each)

<3> Y(0.2) ADEFGHIKLMNPQRSTVW (0.044 each)

47

5 (CDR1 installed as AflII-(SexAI or Kasi) cassette.) For the most preferred 11 length codon 51 (XXX) is omitted; for the preferred 12 length this codon is <2>

----- CDR1 ----->|----- ER2 ----->

 $\langle 1 \rangle \quad \langle 2 \rangle \quad \langle 2 \rangle \quad \langle 3 \rangle$ 

	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60
--	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----

10 Q Q - V - - L A W Y Q Q K P

|cag| - |gtt| - | - | - | - | ctt|gct|tgg|tat|caa|cag|aaa|cct|

SexAI...



For CDR2:

- <1> ADEFGHIKLMNPQRSTVWY 1:1
- <2> S(0.2) ADEFGHIKLMNPQRSTVWY (0.044 each)
- <4> A(0.2) DEFGHIKLMNPQRSTVWY (0.044 each)

5 CDR2 installed as (SexAI or KasI) to (BamHI or RsrII) cassette.)

----- FR2 ----->|----- CDR2 ----->

61 62 63 64 65 66 67 68 69 70 71 72 73 74 75

G Q A P R L L I Y - A S - R -

lggt|cag|gcg|ccg|cgt|tta|ctt|att|tat| - |gct|tct| - |cgc| - |

SexAI.... KasI....

CDR2-->|--- FR3 ----->

<1>

76 77 78 79 80 81 82 83 84 85 86 87 88 89 90

- G I P D R F S G S G S G T D

5 | - |ggg|atc|ccg|gac|cgt|ttc|tct|ggc|tct|ggt|tca|ggt|act|gac|

BamHI...

RsrII.....

----- FR3 ----->

91 92 93 94 95 96 97 98 99 100 101 102 103 104 105

10 F T L T I S R L E P E D F A V

|ttt|acc|ctt|act|att|tct|aga|ttg|gaa|cct|gaa|gac|ttc|gct|gtt|

XbaI...

For CDR3 (Length 9):

<1> ADEFGHIKLMNPQRSTVWY 1:1

15 <3> Y(0.2) ADEFGHIKLMNPQRTVW (0.044 each)

For CDR3 (Length 8): QQ33111P

1 and 3 as defined for Length 9

For CDR3 (Length 10): QQ3211PP1T

1 and 3 as defined for Length 9

5 2 S(0.2) and 0.044 each of ADEFGHIKLMNPQRTWVY

CDR3 installed as XbaI to (StyI or BsiWI) cassette.

```

----->|-----CDR3----->|-----FR4----->
      <3> <1> <1> <1> <1>
106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
      Y  Y  C  Q  Q  -  -  -  -  P  -  T  F  G  Q
|tat|tat|tgc|caa|cag| - | - | - | - |cct| - |act|ttc|ggt|caa|

      BstXI.....

```

```

-----FR4----->|<----- Ckappa -----
121 122 123 124 125 126 127      128 129 130 131 132 133 134
    G  T  K  V  E  I  K          R  T  V  A  A  P  S
|ggt|acc|aag|ggt|gaa|atc|aag|   |cgt|acg|ggt|gcc|gct|cct|agt|
StyI....                          BsiWI...

```

5

```

135 136 137 138 139 140 141 142 143 144 145 146 147 148 149
    V  F  I  F  P  P  S  D  E  Q  L  K  S  G  T
|gtg|ttt|atc|ttt|cct|cct|tct|gac|gaa|caa|ttg|aag|tca|ggt|act|
MfeI...

```

```

10  150 151 152 153 154 155 156 157 158 159 160 161 162 163 164
    A  S  V  V  C  L  L  N  N  F  Y  P  R  E  A
|gct|tct|gtc|gta|tgt|ttg|ctc|aac|aat|ttc|tac|cct|cgt|gaa|gct|
BssSI...

```

165 166 167 168 169 170 171 172 173 174 175 176 177 178 179  
K V Q W K V D N A L Q S G N S  
|aaa|ggt|cag|tgg|aaa|gtc|gat|aac|gcg|ttg|cag|tcg|ggt|aac|agt|

MluI....

180 181 182 183 184 185 186 187 188 189 190 191 192 193 194  
Q E S V T E Q D S K D S T Y S  
|caa|gaa|tcc|gtc|act|gaa|cag|gat|agt|aag|gac|tct|acc|tac|tct|

195 196 197 198 199 200 201 202 203 204 205 206 207 208 209  
L S S T L T L S K A D Y E K H  
|ttg|tcc|tct|act|ctt|act|tta|tca|aag|gct|gat|tat|gag|aag|cat|

210 211 212 213 214 215 216 217 218 219 220 221 222 223 224  
K V Y A C E V T H Q G L S S P  
|aag|gtc|tat|Gct|TGC|gaa|ggt|acc|cac|cag|ggt|ctg|agc|tcc|cct|

SacI....

5

10

225 226 227 228 229 230 231 232 233 234  
V T K S F N R G E C .  
|gtt|acc|aaa|agt|ttc|aac|cgt|ggt|gaa|tgc|taa|tag ggcgcgcc  
DsaI.... AscI....  
BssHII

5

acgcattctctaa gcggccgc aacaggaggag  
NotI....

Table 8: 2a2:JH2 Human lambda-chain gene

gaggaccatt gggccc ttactccgtgac  
Scab..... EcoO109I  
ApaI..

-----FR1----->															
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	
S	A	Q	S	A	L	T	Q	P	A	S	V	S	G	P	G
agt gca caa tcc gct ctc act cag cct gct agc gtt tcc ggg tca cct ggt															
ApaI...					NheI...					BstEII...					
SexAI.....															

For CDR1 (length 14):  
<1> = 0.27 T, 0.27 G, 0.027 each of ADEFGHIKLMNPQRSWY, no C  
<2> = 0.27 D, 0.27 N, 0.027 each of ADEFGHIKLMNPQRSWY, no C  
<3> = 0.36 Y, 0.0355 each of ADEFGHIKLMNPQRSTVW, no C

```

                    T   G   <1>   S   <2>   V   G
-----FR1-----> |-----CDR1-----
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
   Q   S   I   T   I   S   C   T   G   -   S   S   -   V   G
5   |caa|agt|atc|act|att|tct|tgt|aca|ggg| - |tct|tct| - |gtt|ggc|
                                     BsrGI..

```

```

<1> <3> <2> <3>   V   S = vg Scheme #1, length = 14
-----CDR1-----> |-----FR2-----
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
   -   -   -   -   V   S   W   Y   Q   Q   H   P   G   K   A
   | - | - | - | - |gtt|tct|tgg|tat|caa|caa|cac|ccg|ggc|aag|gcg|
                                     XmaI....   KsaI.....
                                     AvaI.....

```

A second Vg scheme for CDR1 gives segments of length 11:

15 T<sub>22</sub>G<2><4>L<4><4><4><3><4><4> where

<4> = equimolar mixture of each of ADEFGHIKLMNPQRSTVWY, no C

<3> = as defined above for the alternative CDR1





-----FR3----->|  
 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90  
 T I S G L Q A E D E A D Y Y C  
 |act|atc|tct|ggt|ctg|cag|gct|gaa|gac|gag|gct|gac|tac|tat|tgt|  
 PstI...

5

CDR3 (Length 11):

<2> and <4> are the same variegation as for CDR1

<5> = 0.36 S, 0.0355 each of ADEFGHIKLMNPQRTVWY no C

CDR3 (Length 10): <5> SY <1> <5> S <5> <1> <4> V

10 <1> is an equimolar mixture of ADEFGHIKLMNPQRTVWY, no C

<4> and <5> are as defined for Length 11

<4> <5> <4> <2> <4> S <4> <4> <4> <4> V

-----CDR3----->|-----FR4-----  
91 92 93 94 95 96 97 98 99 100 101 102 103 104 105  
- - - - - S - - - - V F G G G  
| - | - | - | - | tct| - | - | - | gtc|ttc|ggc|ggg|ggt|  
KpnI...

5

-----FR4----->  
106 107 108 109 110 111 112 113 114 115 116 117 118 119 120  
T K L T V L G Q P K A A P S V  
|acc|aaa|ctt|act|gtc|ctc|ggg|caa|cct|aag|gct|gct|cct|tcc|gtt|  
HincII..  
KpnI...  
Bsu36I...

10

121 122 123 124 125 126 127 128 129 130 131 132 133 134 135  
T L F P P S S E E L Q A N K A  
|act|ctc|ttc|cct|cct|agt|tct|gaa|gag|ctt|caa|gct|aac|aag|gct|  
SapI.....

15

136 137 138 139 140 141 142 143 144 145 146 147 148 149 150  
T L V C L I S D F Y P G A V T  
|act|ctt|ggt|tgc|ttg|atc|agt|gac|ttt|tat|cct|ggt|gct|ggt|act|  
BclI....

5 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165  
V A W K A A D S S P V K A G V E  
|gtc|gct|tgg|aaa|gcc|gat|tct|tct|cct|ggt|aaa|gct|ggt|ggt|gag|  
BsmBI....

10 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180  
T T T P S K Q S N N K Y A A S  
|acg|acc|act|cct|tct|aaa|caa|tct|aac|aat|aag|tac|gct|gcg|agc|  
BsmBI.... SacI....

15 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195  
S Y L S L T P E Q W K S H K S  
|tct|tat|ctt|tct|ctc|acc|cct|gaa|caa|tgg|aag|tct|cat|aaa|tcc|  
SacI....

196 197 198 199 200 201 202 203 204 205 206 207 208 209 210  
Y S C Q V T H E G S T V E K T  
|tat|tcc|tgt|caa|ggt|act|cat|gaa|ggt|tct|acc|ggt|gaa|aag|act|

BspHI...

211 212 213 214 215 216 217 218 219

V A P T E C S . .

|ggt|gcc|cct|act|gag|tgt|tct|tag|tga|ggcgcgcc

Ascl....

BssHII

10 aacgatgttc aag gcggccgc aacaggaggag

NotI.... Scab.....

**Table 9: Oligonucleotides For Kappa and Lambda Light Chain Variegation**

(Ctop25): 5'-gctctggtcaac|tta|agg|gct|gag|g-3'  
 (CtpmA): 5'-gctctggtcaac|tta|agg|gct|gag|gac|acc|gct|gct|tac|tac|tgc|gcc-3'  
 AFLII...  
 (CBprmB) [RC]: 5'-|tac|ttc|gat|tac|ttg|ggc|caa|ggg|acc|ctg|gtc|acc|tcgctccacc-3'  
 BstEII...  
 (CBot25) [RC]: 5'-|ggg|acc|ctg|gtc|acc|tcgctccacc-3'

**Kappa chains: CDR1 ("1"), CDR2 ("2"), CDR3 ("3")**

10 **CDR1**  
 (Ka1Top610): 5'-gggtctcagttg|cta|agc|ccg|ggg|gaa|cgt|gct|acc|tta|agt|tgc|cgt|gct|tcc|cag-3'  
 (Ka1STp615): 5'-gggtctcagttg|cta|agc|ccg|ggg|g-3'  
 (Ka1Bot620) [RC]: 5'-ctt|gct|tgg|tat|caa|cag|aaa|cct|ggg|cag|gcg|ccaagtcgtgtc-3'  
 (Ka1SB625) [RC]: 5'-cct|ggg|cag|gcg|ccaagtcgtgtc-3'

(Ka1vg600): 5'-gct|acc|tta|agt|tgc|cgt|gct|tcc|cag-  
 |<1>|gtt|<2>|<3>|ctt|gct|tgg|tat|caa|cag|aaa|cc-3'  
 (Ka1vg600-12): 5'-gct|acc|tta|agt|tgc|cgt|gct|tcc|cag-  
 |<1>|gtt|<2>|<2>|<3>|ctt|gct|tgg|tat|caa|cag|aaa|cc-3'

## 5 CDR2

(Ka2Tshort657): 5'-cacgagtccta|cct|ggg|cag|gc-3'  
 (Ka2Tlong655): 5'-cacgagtccta|cct|ggg|cag|gcg|ccg|cgt|tta|ctt|att|tat-3'  
 (Ka2Bshort660): [RC]: 5'-|gac|cgt|ttc|tct|ggg|tctcacc-3'  
 (Ka2vg650): 5'-cag|gcg|ccg|cgt|tta|ctt|att|tat|<1>|gct|tct|<2>|-  
 |cgc|<4>|<1>|ggg|atc|ccg|gac|cgt|ttc|tct|ggg|tctcacc-3'

10

## CDR3

(Ka3Tlon672): 5'-gacgagtccttct|aga|ttg|gaa|cct|gaa|gac|ttc|gct|ggt|tat|tat|tgc|caa|c-3'  
 (Ka3BotI682) [RC]: 5'-act|ttc|ggg|caa|ggg|acc|aag|ggt|gaa|atc|aag|cgt|acg|tcacaggtgag-3'  
 (Ka3Bsho694) [RC]: 5'-gaa|atc|aag|cgt|acg|tcacaggtgag-3'

(Ka3vg670): 5'-gac|ttc|gct|ggt|-  
 |tat|tat|tgc|caa|cag|<3>|<1>|<1>|<1>|cct|<1>|act|ttc|ggt|caa|-  
 |ggt|acc|aag|ggt|g-3'  
 (Ka3vg670-8): 5'-gac|ttc|gct|ggt|-  
 |tat|tat|tgc|caa|cag|<3>|<1>|<1>|<1>|cct|ttc|ggt|caa|-  
 |ggt|acc|aag|ggt|g-3'  
 (Ka3vg670-10): 5'-gac|ttc|gct|ggt|tat|-  
 |tat|tgc|caa|cag|<3>|<2>|<1>|<1>|cct|cct|<1>|act|ttc|ggt|caa|-  
 |ggt|acc|aag|ggt|g-3'

5

10 **Lambda Chains: CDR1 ("1"), CDR2 ("2"), CDR3 ("3")**

#### CDR1

(Lm1TPri75): 5'-gacgagtcctgg|tca|cct|ggt|-3'  
 (Lm1tlo715): 5'-gacgagtcctgg|tca|cct|ggt|caa|agt|atc|act|att|tct|tgt|aca|ggt|-3'  
 (Lm1blo724) [rc]: 5'-gtt|tct|tgg|tat|caa|caa|cac|ccg|ggc|aag|gcg|agatcttcacaggtgag-3'  
 (Lm1bsh737) [rc]: 5'-gc|aag|gcg|agatcttcacaggtgag-3'  
 (Lm1vg710b): 5'-gt|atc|act|att|tct|tgt|aca|ggt|<2>|<4>|ctc|<4>|<4>|<4>|<3>|<4>|<4>|tgg|tat|caa|caa|cac|cc-3'

15



(Lm1vg710): 5'-gt|atc|act|att|tct|tgt|aca|ggt|<1>|tct|tct|<2>|gtt|ggc| -  
 |<1>|<3>|<2>|<3>|gtt|tct|tggt|tat|caa|cac|cc-3'

## CDR2

(Lm2TSh757): 5'-gagcagaggac|ccg|ggc|aag|gc-3'  
 5 (Lm2TLo753): 5'-gagcagaggac|ccg|ggc|aag|gcg|ccg|aag|ttg|atg|atc|tac|-3'  
 (Lm2BLo762) [RC]: 5'-cgt|cct|tct|ggt|gtc|agc|aat|cgt|ttc|tcc|gga|tcacaggtgag-3'  
 (Lm2BSh765) [RC]: 5'-cgt|ttc|tcc|gga|tcacaggtgag-3'  
 (Lm2vg750): 5'-g|ccg|aag|ttg|atg|atc|tac| -  
 <4>|<4>|<4>|<2>|cgt|cct|tct|ggt|gtc|agc|aat|c-3'

## 10 CDR3

(Lm3TSh822): 5'-ctg|cag|gct|gaa|gac|gag|gct|gac-3'  
 (Lm3TLo819): 5'-ctg|cag|gct|gaa|gac|gag|gct|gac|tac|tat|tgt|-3'  
 (Lm3BLo825) [RC]: 5'-gtc|ttc|ggc|ggt|ggt|acc|aaa|ctt|act|gtc|ctc|ggt|caa|cct|aag|g-  
 acacaggtgag-3'

15 (Lm3BSh832) [RC]: 5'-c|ggt|caa|cct|aag|gacacaggtgag-3'

(Lm3vg817): 5'-gac|gag|gct|gac|tac|tat|tgt|-  
|<4>|<5>|<4>|<2>|<4>|tct|<4>|<4>|<4>|<4>|-  
Gtc|ttc|ggc|ggt|ggt|acc|aaa|ctt|ac-3'  
(Lm3vg817-10): 5'- gac|gag|gct|gac|tac|tat|tgt|-  
|<5>|agc|tat|<1>|<5>|tct|<5>|<1>|<4>|gtc|ttc|ggc|ggt|ggt|-  
|acc|aaa|ctt|ac-3'

5

**Table 10: A27:JH1 Kappa light chain gene with stuffers in place of CDRs**

Each stuffer contains at least one stop codon and a restriction site that will be unique within the diversity vector.

gaggacc attggggccc ctccgagact ctcgagcgca

5 Scab.....EcoO109I

Apal.

XhoI..

acgcaattaa tgtgagtttag ctcaactcatt aggcacccca ggctttacac tttatgcttc

..-35..

Plac

..-10.

10 cggtctcgtat gttgtgtgga attgtgagcg gataacaatt tcacacagga aacagctatgac

catgatta cgccaagctt tggagccctt tttttggaga ttttcaac

Pf1MI.....

Hind3.

M13 III signal sequence (AA seq)----->

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15  
M K K L L F A I P L V V P F Y  
gtg aag aag ctc cta ttt gct atc ccg ctt gtc gtt ccg ttt tac

5 --Signal--> FR1----->  
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30  
S H S A Q S S V L T Q S P G T L  
lagc|cat|agt|gca|caa|tcc|gtc|ctt|act|caa|tct|cct|ggc|act|ctt|  
ApaI...

10 ----- FR1 ----->|-----Stuffer->  
31 32 33 34 35 36 37 38 39 40 41 42 43  
S L S P G E R A T L S | |  
|tcg|cta|agc|ccg|ggg|gaa|cgt|gct|acc|tta|agt|tag|taa|gct|ccc|  
EspI..... AflII...

15 XmaI.....

```

5  - Stuffer for CDR1--> FR2 ----->|-----Stuffer for CDR2
    59 60 61 62 63 64 65 66
      K P G Q A P R
    |agg|cct|ctt|tga|tct|g|aaa|cct|ggg|cag|gag|ccg|cgt|taa|tga|aagcgctaattggccaacagtg
    StuI...      SexAI... KasI....      AfeI.. MscI..

```

```

10 Stuffer-->|--- FR3 ----->
    76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
      T G I P D R F S G S G S G T D
    |act|ggg|atc|ccg|gac|cgt|ttc|tct|ggc|tct|ggg|tca|ggt|act|gac|
      BamHI...
      RsrII.....

```

```

----- FR3 ----->-----STUFFER for CDR3----->
91 92 93 94 95 96 97
F T L T I S R I I
|ttt|acc|ctt|act|att|tct|aga|taa|tga| gttaac tag acc tacgta acc tag
XbaI... HpaI... SnaBI.

-----CDR3 stuffer----->|-----FR4----->
118 119 120
F G Q
|ttc|ggg|caa|

-----FR4----->|<----- Ckappa -----
121 122 123 124 125 126 127 128 129 130 131 132 133 134
G T K V E I K R T V A A P S
|ggg|acc|aag|ggt|gaa|atc|aag| |cgt|acg|ggt|gcc|gct|cct|agt|
StyI.... BsiWI..

```

5

10

135 136 137 138 139 140 141 142 143 144 145 146 147 148 149  
V F I F P P S D E Q L K S G T  
|gtg|ttt|atc|ttt|cct|cct|tct|gac|gaa|caa|ttg|aag|tca|ggt|act|  
MfeI...

5 acgcatctcttaa gcggccgc aacaggaggag

NotI....

EagI..

Table 11: 2a2:JH2 Human lambda-chain gene with stuffers in place of CDRs

gaggaccatt gggcccc ttactccgtgac  
Scab..... EcoO109I  
ApaI..

5

-----FR1----->  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15  
S A Q S A L T Q P A S V S G S P G  
agt|gca|caa|tcc|gct|ctc|act|cag|cct|gct|agc|gtt|tcc|ggg|tca|cct|ggt|  
ApaI... NheI... BstEII... SexAI....

10

-----FR1-----> |-----stuffer for CDR1-----  
16 17 18 19 20 21 22 23  
Q S I T I S C T  
|caa|agt|atc|act|att|tct|tgt|aca|tct tag tga ctc  
BsrGI..

15



```
-----Stuffer----->-----FR2----->
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
R S I I P I H P G K A
aga tct taa tga ccg tag cac|ccg|ggc|aag|gcg|
5 BglII XmaI.... KasI.....
AvaI....

--|-----Stuffer for CDR2 ----->
P
|ccg|taa|tgalatc tcg tac g ct|ggg|gtt|
10 KasI.... BsiWI...

-----FR3-----
61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
S N R R F S G S K S G N T A S L
|agc|aat|cgt|ttc|tcc|gga|tct|aaa|tcc|ggg|aat|acc|gca|agc|tta|
BspEI.. HindIII.
15 BsaBI.....(blunt)
```

```

-----FR3----->|---Stuffer for CDR3----->|
76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
T I S G L Q
|act|atc|tct|ggg|ctg|cag|gtt ctg tag ttc caattg ctt tag tga ccc
PstI... MfeI..

```

5

```

-----Stuffer----->|---FR4----->|
103 104 105
G G G
|ggc|ggg|ggg|
KpnI...

```

10

```

-----FR4----->
106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
T K L T V L G Q P K A A P S V
|acc|aaa|ctt|act|gtc|ctc|ggg|caa|cct|aag|gct|gct|cct|tcc|gtt|
KpnI... HincII..
Bsu36I...

```

15

121 122 123 124 125 126 127 128 129 130 131 132 133 134 135  
T L F P P S S E E L Q A N K A  
|act|ctc|ttc|cct|cct|agt|tct|gaa|gag|ctt|caa|gct|aac|aag|gct|  
SapI.....

5 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150  
T L V C L I S D F Y P G A V T  
|act|ctt|gtt|tgc|ttg|atc|agt|gac|ttt|tat|cct|ggg|gct|gtt|act|  
BclI....

- 75 -

I claim:

1. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a heavy chain CDR1 selected from the group consisting of:

(1)  $\langle 1 \rangle_1 Y_2 \langle 1 \rangle_3 M_4 \langle 1 \rangle_5$ , wherein  $\langle 1 \rangle$  is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y;

(2)  $(S/T)_1 (S/G/X)_2 (S/G/X)_3 Y_4 Y_5 W_6 (S/G/X)_7$ .

wherein (S/T) is a 1:1 mixture of S and T residues, (S/G/X) is a mixture of 0.2025 S, 0.2025 G and 0.035 of each of amino acid residues A, D, E, F, H, I, K, L, M, N, P, Q, R, T, V, W, and Y;

(3)  $V_1 S_2 G_3 G_4 S_5 I_6 S_7 \langle 1 \rangle_8 \langle 1 \rangle_9 \langle 1 \rangle_{10} Y_{11} Y_{12} W_{13} \langle 1 \rangle_{14}$ ,

wherein  $\langle 1 \rangle$  is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; and

(4) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

2. The focused library according to claim 1, wherein HC CDR1s (1), (2) and (3) are present in the library in the ratio 0.80:0.17:0.02.

3. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively

- 76 -

display, display and express, or comprise at least a portion of the diversity of the antibody facility, the vectors or genetic packages being characterized by variegated DNA sequences that encode a heavy chain CDR2 selected from the group consisting of:

(1) <2>I<2><3>SGG<1>T<1>YADSVKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <2> is an equimolar mixture of each of amino acid residues Y, R, W, V, G, and S; and <3> is an equimolar mixture of each of amino acid residues P, S, and G or an equimolar mixture of P and S;

(2) <1>I<4><1><1><G><5><1><1><1>YADSVKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <4> is an equimolar mixture of residues D, I, N, S, W, Y; and <5> is an equimolar mixture of residues S, G, D and N;

(3) <1>I<4><1><1><G><5><1><1>YNPSLKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and <4> and <5> are as defined above;

(4) <1>I<8>S<1><1><1>GGYY<1>YAASVKG, wherein <1> is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; <8> is 0.27 R and 0.027 of each of ADEFGHIKLMNPQSTVWY; and

(5) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

4. The focused library according to claim 3 wherein a mixture of HC CDR2s (1)/(2) (equimolar), (3) and

- 77 -

(4) are present in the library in a ratio of 0.54:0.43:0.03.

5. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a heavy chain CDR3 selected from the group consisting of:

(1) YYCA21111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(2) YYCA211111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(3) YYCA2111111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(4) YYCAR111S2S3111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of Y and W;

(5) YYCA2111CSG11CY1YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

- 78 -

(6) YYCA211S1TIFG11111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(7) YYCAR111YY2S3344111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; 2 is an equimolar mixture of D and G; and 3 is an equimolar mixture of S and G;

(8) YYCAR1111YC2231CY111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of T, D and G; and

(9) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

6. The focused library according to claim 5, wherein 1 in one or all of HC CDR3s (1) through (8) is 0.095 of each of G and Y and 0.048 of each of A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, and W.

7. The focused library according to claim 5 or 6, wherein HC CDR3s (1) through (8) are present in the library in the following proportions:

- (1) 0.10
- (2) 0.14
- (3) 0.25
- (4) 0.13
- (5) 0.13
- (6) 0.11
- (7) 0.04 and
- (8) 0.10

- 79 -

8. The focused library according to claim 5 or 6, wherein the HC CDR3s (1) through (8) are present in the library in the following proportions:

- (1) 0.02
- (2) 0.14
- (3) 0.25
- (4) 0.14
- (5) 0.14
- (6) 0.12
- (7) 0.08 and
- (8) 0.11

9. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encodes a kappa light chain CDR1 selected from the group consisting of:

- (1) RASQ<1>V<2><2><3>LA
- (2) RASQ<1>V<2><2><2><3>LA;

wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <3> is 0.2Y and 0.044 each of ADEFGHIKLMNPQRTVW and Y; and

- (3) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

10. The focused library of claim 9, wherein CDR1s (1) and (2) are present in the library in a ratio of 0.68:0.32.



- 80 -

11. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a kappa light chain CDR2 having the sequence:

<1>AS<2>R<4><1>,

wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <4> is 0.2 A and 0.044 each of DEFGHIKLMNPQRSTVWY.

12. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a kappa light chain CDR3 selected from the groups consisting of:

(1) QQ<3><1><1><1>P<1>T,

wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <3> is 0.2 Y and 0.044 each of ADEFGHIKLMNPQRTVW;

(2) QQ33111P, wherein 1 and 3 are as defined in (1) above;

- 81 -

(3) QQ3211PP1T, wherein 1 and 3 are as defined in (1) above and 2 is 0.2 S and 0.044 each of ADEFGHIKLMNPQRTVWY; and

(4) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

13. The focused library according to claim 12, wherein CDR3s (1), (2) and (3) are present in the library in a ratio of 0.65:0.1:0.25.

14. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a lambda light chain CDR1 selected from the group consisting of:

(1) TG<1>SS<2>VG<1><3><2><3>VS,  
wherein <1> is 0.27 T, 0.27 G and 0.027 each of ADEFHIKLMNPQRSVWY, <2> is 0.27 D, 0.27 N and 0.027 each of AEFGHIKLMPQRSTVWY, and <3> is 0.36 Y and 0.036 each of ADEFGHIKLMNPQRTVW;

(2) G<2><4>L<4><4><3><4><4>,  
wherein <2> is as defined in (1) above and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRTVWY; and

(3) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

- 82 -

15. The focused library according to claim 14, where CDR1s (1) and (2) are present in the library in a ratio of 0.67:0.33.

16. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a lambda light chain CDR2 has the sequence:

<4><4><4><2>RPS,

wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEFQHIKLMNPQRSTVWY and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW.

17. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a lambda light chain CDR3 selected from the group consisting of:

(1) <4><5><4><2><4>S<4><4><4><4>V,

wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEFQHIKLMNPQRSTVWY; <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW; and <5> is 0.36 S and 0.0355 each of ADEFGHIKLMNPQRTVWY;

- 83 -

(2) <5>SY<1><5>S<5><1><4>V, wherein <1> is an equimolar mixture of ADEFGHIKLMNPQRSTVWY; and <4> and <5> are as defined in (1) above; and

(3) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

18. The focused library according to claim 17, wherein CDR3s (1) and (2) are present in the library in an equimolar mixture.

19. The focused library according to claim 1 or 2 further comprising variegated DNA sequences that encode a heavy chain CDR selected from the group consisting of:

(1) one or more of the heavy chain CDR2s defined in claim 3 or 4;

(2) one or more of the heavy chain CDR3s defined in claims 5, 6, 7, or 8; and

(3) mixtures of vectors or genetic packages characterized by (1) and (2).

20. The focused library according to claim 3 further comprising variegated DNA sequences that encodes one or more heavy chain CDR3s selected from the group defined in claims 5, 6, 7 or 8.

21. The focused library according to claim 19 or 20, further comprising variegated DNA sequences that encodes a light chain CDR selected from the group consisting of

(1) one or more the kappa light chain CDR1s defined in claim 9 or 10;

(2) the kappa light chain CDR2 defined in claim 11;

- 84 -

(3) one or more of the kappa light chain CDR3s defined in claim 12 or 13;

(4) one or more of the kappa light chain CDR1s defined in claim 14 or 15;

(5) the lambda light chain CDR2 defined in claim 16;

(6) one or more of the lambda light chain CDR3s defined in claim 17 or 18; and

(7) mixtures of vectors and genetic packages characterized by one or more of (1) through (6).

22. A population of variegated DNA sequences that encode a heavy chain CDR1 selected from the group consisting of:

(1)  $\langle 1 \rangle_1 Y_2 \langle 1 \rangle_3 M_4 \langle 1 \rangle_5$ , wherein  $\langle 1 \rangle$  is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y;

(2)  $(S/T)_1 (S/G/X)_2 (S/G/X)_3 Y_4 Y_5 W_6 (S/G/X)_7$ , wherein (S/T) is a 1:1 mixture of S and T residues, (S/G/X) is a mixture of 0.2025 S, 0.2025 G and 0.035 of each of amino acid residues A, D, E, F, H, I, K, L, M, N, P, Q, R, T, V, W, and Y;

(3)  $V_1 S_2 G_3 G_4 S_5 I_6 S_7 \langle 1 \rangle_8 \langle 1 \rangle_9 \langle 1 \rangle_{10} Y_{11} Y_{12} W_{13} \langle 1 \rangle_{14}$ , wherein  $\langle 1 \rangle$  is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; and

(4) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

23. The population of variegated DNA sequences according to claim 22, wherein HC CDR1s (1), (2) and (3) are present in the population in the ratio 0.80:0.17:0.02.

- 85 -

24. A population of variegated DNA sequences that encode a heavy chain CDR2 selected from the group consisting of:

(1) <2>I<2><3>SGG<1>T<1>YADSVKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <2> is an equimolar mixture of each of amino acid residues Y, R, W, V, G, and S; and <3> is an equimolar mixture of each of amino acid residues P, S, and G or an equimolar mixture of P and S;

(2) <1>I<4><1><1><G><5><1><1><1>YADSVKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <4> is an equimolar mixture of residues D, I, N, S, W, Y; and <5> is an equimolar mixture of residues S, G, D and N;

(3) <1>I<4><1><1><G><5><1><1>YNPSLKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and <4> and <5> are as defined above;

(4) <1>I<8>S<1><1><1>GGYY<1>YAASVKG, wherein <1> is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; <8> is 0.27 R and 0.027 of each of ADEFGHIKLMNPQSTVWY; and

(5) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

25. The population of variegated DNA sequences according to claim 24, wherein a mixture of HC CDR2s (1)/(2) (equimolar), (3) and (4) are present in the population in a ratio of 0.54:0.43:0.03.

- 86 -

26. A population of variegated DNA sequences that encode a heavy chain CDR3 selected from the group consisting of:

(1) YYCA21111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(2) YYCA2111111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(3) YYCA211111111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(4) YYCAR111S2S3111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of Y and W;

(5) YYCA2111CSG11CY1YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(6) YYCA211S1TIFG11111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(7) YYCAR111YY2S3344111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; 2 is an equimolar mixture of D and G; and 3 is an equimolar mixture of S and G;

- 87 -

(8) YYCAR1111YC2231CY111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of T, D and G; and

(9) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

27. The population of variegated DNA according to claim 26, wherein 1 in one or all of HC CDR3s (1) through (8) is 0.095 of each of G and Y and 0.048 of each of A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, and W.

28. The population of variegated DNA sequences according to claim 26 or 27, wherein HC CDR3s (1) through (8) are present in the population in the following proportions:

- (1) 0.10
- (2) 0.14
- (3) 0.25
- (4) 0.13
- (5) 0.13
- (6) 0.11
- (7) 0.04 and
- (8) 0.10

29. The population of variegated DNA sequences according to claim 26 or 27, wherein the HC CDR3s (1) through (8) are present in the population in the following proportions:

- (1) 0.02
- (2) 0.14
- (3) 0.25



- 88 -

- (4) 0.14
- (5) 0.14
- (6) 0.12
- (7) 0.08 and
- (8) 0.11

30. A population of variegated DNA sequences that encode a kappa light chain CDR1 selected from the group consisting of:

- (1) RASQ<1>V<2><2><3>LA
- (2) RASQ<1>V<2><2><2><3>LA;

wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <3> is 0.2Y and 0.044 each of ADEFGHIKLMNPQRTVW and Y; and

(3) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

31. The population of variegated DNA sequences of claim 30, wherein CDR1s (1) and (2) are present in the population in a ratio of 0.68:0.32.

32. A population of variegated DNA sequences that encode a kappa light chain CDR2 having the sequence:

<1>AS<2>R<4><1>,

wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <4> is 0.2 A and 0.044 each of DEFGHIKLMNPQRSTVWY.

33. A population of variegated DNA sequences that encode a kappa light chain CDR3 selected from the groups consisting of:

- 89 -

(1) QQ<3><1><1><1>P<1>T,

wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <3> is 0.2 Y and 0.044 each of ADEFGHIKLMNPQRTVW;

(2) QQ33111P, wherein 1 and 3 are as defined in (1) above;

(3) QQ3211PP1T, wherein 1 and 3 are as defined in (1) above and 2 is 0.2 S and 0.044 each of ADEFGHIKLMNPQRTVWY; and

(4) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

34. The population of variegated DNA sequences according to claim 33, wherein CDR3s (1), (2) and (3) are present in the population in a ratio of 0.65:0.1:0.25.

35. A population of variegated DNA sequences that encode a lambda light chain CDR1 selected from the group consisting of:

(1) TG<1>SS<2>VG<1><3><2><3>VS,

wherein <1> is 0.27 T, 0.27 G and 0.027 each of ADEFGHIKLMNPQRSVWY, <2> is 0.27 D, 0.27 N and 0.027 each of ADEFGHIKLMPQRTVWY, and <3> is 0.36 Y and 0.036 each of ADEFGHIKLMNPQRTVW;

(2) G<2><4>L<4><4><4><3><4><4>,

wherein <2> is as defined in (1) above and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRTVWY; and

(3) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

- 90 -

36. The population of variegated DNA sequences according to claim 35, where CDR1s (1) and (2) are present in the population in a ratio of 0.67:0.33.

37. A population of variegated DNA sequences that encode a lambda light chain CDR2 has the sequence:

<4><4><4><2>RPS,

wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEF~~G~~HIKLM~~P~~QRSTVWY and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW.

38. A population of variegated DNA sequences that encode a lambda light chain CDR3 selected from the group consisting of:

(1) <4><5><4><2><4>S<4><4><4><4>V,

wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEF~~G~~HIKLM~~P~~QRSTVWY; <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW; and <5> is 0.36 S and 0.0355 each of ADEFGHIKLMNPQRTVWY;

(2) <5>SY<1><5>S<5><1><4>V, wherein <1> is an equimolar mixture of ADEFGHIKLMNPQRSTVWY; and <4> and <5> are as defined in (1) above; and

(3) mixtures of variegated DNA sequence characterized by any of the above DNA sequences.

39. The population of variegated DNA sequences according to claim 38, wherein CDR3s (1) and (2) are present in the population in an equimolar mixture.

40. The population of variegated DNA sequences according to claim 22 or 23 further comprising variegated DNA sequences that encode a heavy chain CDR selected from the group consisting of:

- 91 -

(1) one or more of the heavy chain CDR2s defined in claim 24 or 25;

(2) one or more of the heavy chain CDR3s defined in claims 26, 27, 28 or 29; and

(3) mixtures of variegated DNA sequence characterized by (1) and (2).

41. The population of variegated DNA sequences according to claim 24 further comprising variegated DNA sequences that encodes one or more heavy chain CDR3s selected from the group defined in claims 26, 27, 28 or 29.

42. The population of variegated DNA sequences according to claim 40 or 41 further comprising variegated DNA sequences that encodes a light chain CDR selected from the group consisting of

(1) one or more the kappa light chain CDR1s defined in claim 30 or 31;

(2) the kappa light chain CDR2 defined in claim 32;

(3) one or more of the kappa light chain CDR3s defined in claim 33 or 34;

(4) one or more of the kappa light chain CDR1s defined in claim 35 or 36;

(5) the lambda light chain CDR2 defined in claim 37;

(6) one or more of the lambda light chain CDR3s defined in claim 38 or 39; and

(7) mixtures of variegated DNA sequences characterized by one or more of (1) through (6).

43. A population of vectors comprising the variegated DNA sequences of any one of claims 22-42.